Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | VLS-101 |
Trade Name | |
Synonyms | VLS 101|VLS101|Zilovertamab Vedotin|MK 2140|MK2140|MK-2140 |
Drug Descriptions |
VLS-101 is an antibody-drug conjugate (ADC) comprising a ROR1-targeted antibody linked to monomethyl auristatin E (MMAE), which delivers the drug to ROR1-expressing tumor cells, potentially resulting in increased apoptosis and decreased tumor growth (Blood (2019) 134 (Supplement_1): 2856). |
DrugClasses | ROR1 Antibody 7 |
CAS Registry Number | 2376463-48-6 |
NCIT ID | C157772 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ARQ 531 + VLS-101 | ARQ 531 VLS-101 | 0 | 1 |
Bendamustine + Rituximab + VLS-101 | Bendamustine Rituximab VLS-101 | 0 | 1 |
Cyclophosphamide + Doxorubicin + Rituximab + VLS-101 | Cyclophosphamide Doxorubicin Rituximab VLS-101 | 0 | 1 |
Gemcitabine + Oxaliplatin + Rituximab + VLS-101 | Gemcitabine Oxaliplatin Rituximab VLS-101 | 0 | 1 |
VLS-101 | VLS-101 | 0 | 6 |